Jaklitinib Ruxolitinib — Targeted therapy for myelofibrosis, polycythaemia vera, and graft-versus-host disease. Available in 15mg and 5mg.
Targeted Therapy

Jaklitinib (Ruxolitinib)

Available strengths

  • 15mg
  • 5mg
Jaklitinib (Ruxolitinib) product packs in 5mg and 15mg strengths

Patient Information

Frequently Asked Questions (FAQs)

Jaklitinib is used to treat:

  • Adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.
  • Adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
  • Adults and children aged 2 years and older with graft-versus-host disease (GvHD).

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

  • Myelofibrosis (Adults): The recommended starting dose is 5 to 20 mg twice daily. The maximum dose is 25 mg twice daily.
  • Polycythaemia vera (Adults): The recommended starting dose is 10 mg twice daily. The maximum dose is 25 mg twice daily.
  • Acute and chronic graft-versus-host disease: Children 6–12 years old: the recommended starting dose is 5 mg twice daily. Children 12 years and older and adults: the recommended starting dose is 10 mg twice daily.
  • If you forget to take Jaklitinib: Simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

Myelofibrosis and polycythaemia vera — Very common:

  • Any sign of bleeding in the stomach or intestine, such as passing black or bloodstained stools, or vomiting blood.
  • Unexpected bruising and/or bleeding, unusual tiredness, shortness of breath, unusually pale skin, or frequent infections.
  • Painful skin rash with blisters (possible symptoms of shingles).
  • Fever, chills or other symptoms of infections.
  • Low level of red blood cells (anaemia), white blood cells (neutropenia), or platelets (thrombocytopenia).

Graft-versus-host disease (GvHD) — Very common:

  • Fever, pain, redness, and/or difficulty breathing (possible cytomegalovirus infection).
  • Fever, pain when urinating (possible urinary tract infection).
  • Fast heart rate, fever, confusion and rapid breathing (possible sepsis).
  • Tiredness, fatigue, pale skin, frequent infections, fever, chills, sore throat or mouth ulcers (possible anaemia or neutropenia).
  • Spontaneous bleeding or bruising (possible thrombocytopenia).
  • Low counts of all three types of blood cells (pancytopenia).

Other side effects — Very common:

  • High level of cholesterol (hypercholesterolaemia), headache, high blood pressure (hypertension), feeling sick (nausea).
  • Abnormal liver function test results.
  • Increased blood level of creatine phosphokinase and increased blood creatinine.

Do not take Jaklitinib

  • If you are allergic to ruxolitinib or any of the other ingredients of this medicine.
  • If you are pregnant or breast-feeding.

Warnings and precautions

Talk to your doctor or pharmacist before taking Jaklitinib if:

  • You have any infections. It may be necessary to treat your infection before starting Jaklitinib.
  • You have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis.
  • You have ever had hepatitis B.
  • You have kidney problems.
  • You have or have ever had liver problems. Your doctor may need to prescribe a different dose of Jaklitinib.
  • You have ever had cancer, in particular skin cancer.
  • You have or have had heart problems.
  • You are 65 years of age or older.
  • You are a smoker or have smoked in the past.

Need more information about Jaklitinib?

Share your product inquiry with the Oncogen Pharma team. We will respond with relevant information for formal healthcare, partnership, or product availability discussions.

Get in Touch